The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol
Status:
Recruiting
Trial end date:
2026-01-22
Target enrollment:
Participant gender:
Summary
The aim of this study is to test whether the realization of 3 courses of intra-arterial
chemotherapy of idarubicin-lipiodol without embolization, administered non-selectively in the
hepatic artery, following the percutaneous tumour ablation of a hepatocellular carcinoma,
could constitute an effective adjuvant treatment to reduce the rates of local and
intrahepatic distant recurrence and thus improve the survival without hepatic progression.